Publications
164 results found
Innes AJ, Beattie R, Sergeant R, et al., 2013, Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT, BONE MARROW TRANSPLANTATION, Vol: 48, Pages: 1324-1328, ISSN: 0268-3369
- Author Web Link
- Cite
- Citations: 9
Deplano S, May PC, Pavlu J, 2013, Double minutes with <i>MYC</i> amplification in a patient with chronic myelomonocytic leukaemia transformed into acute myeloid leukaemia, BRITISH JOURNAL OF HAEMATOLOGY, Vol: 162, Pages: 720-720, ISSN: 0007-1048
- Author Web Link
- Cite
- Citations: 1
Iskander D, Apperley JF, Pavlu J, 2013, Stem cell transplantation and high-dose chemotherapy, Advances in the Treatment of Chronic Myeloid Leukemia, Pages: 63-76, ISBN: 9781780842752
Rotolo A, Pavlu J, Davidson H, et al., 2013, LACE reduced intensity conditioning for high-risk haematological malignancies: a 22-year single-centre experience, 39th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT), Publisher: NATURE PUBLISHING GROUP, Pages: S235-S235, ISSN: 0268-3369
Innes AJ, Lurkins J, Szydlo R, et al., 2013, Long-term leukaemia control following DLI is independent of disease eradication, 39th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT), Publisher: NATURE PUBLISHING GROUP, Pages: S251-S251, ISSN: 0268-3369
Innes AJ, Beattie R, Sergeant R, et al., 2013, HLA-mismatched donor lymphocyte infusion is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allogeneic stem cell transplantation, 39th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT), Publisher: NATURE PUBLISHING GROUP, Pages: S86-S87, ISSN: 0268-3369
Auner HW, Szydlo R, Rone A, et al., 2013, Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation, BONE MARROW TRANSPLANTATION, Vol: 48, Pages: S199-S199, ISSN: 0268-3369
Mactier CE, Beckerson J, Palanicawandar R, et al., 2013, Enteral-based nutrition is associated with better early outcomes in allogeneic myeloablative haematopoietic stem cell transplantation, 39th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT), Publisher: NATURE PUBLISHING GROUP, Pages: S347-S347, ISSN: 0268-3369
Gabriel IH, Sergeant R, Szydlo R, et al., 2013, Donor KIR2DS2/DL2 genotype status is associated with an increased incidence of severe acute graft-versus-host disease following myeloablative haematopoeitic stem cell transplantation, 39th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT), Publisher: NATURE PUBLISHING GROUP, Pages: S19-S19, ISSN: 0268-3369
Pavlu J, Apperley JF, 2013, Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia, CURRENT HEMATOLOGIC MALIGNANCY REPORTS, Vol: 8, Pages: 43-51, ISSN: 1558-8211
- Author Web Link
- Cite
- Citations: 4
Neave EL, Schwarb H, Shlebak A, et al., 2013, Lymphodepletion chemotherapy followed by donor leukocytes for post-transplantation relapse of myelofibrosis after previous donor leukocyte infusion failure, EUROPEAN JOURNAL OF HAEMATOLOGY, Vol: 90, Pages: 76-78, ISSN: 0902-4441
- Author Web Link
- Cite
- Citations: 1
Pavlu J, Chakrabartty J, Apperley JF, 2012, "Stem cell transplantation: Its importance today": Chronic myeloid leukaemia: Stem cell transplantation versus new drugs, Memo - Magazine of European Medical Oncology, Vol: 5, Pages: 277-280, ISSN: 1865-5041
Allogeneic stem cell transplantation (SCT) had traditionally been the first-line therapy of chronic myeloid leukaemia (CML), but the introduction of tyrosine kinase inhibitors (TKI) has caused a major change to the treatment algorithm. The majority of patients in chronic phase obtain an excellent response to these oral agents with minimal toxicity. SCT is therefore used only in a minority of patients who do not achieve adequate response to first-, second- or even third-generation agents. Patients in accelerated phase are less likely to achieve an optimal response and for patients in blast phase, SCT continues to be the only therapy with curative potential although it is now increasingly used in combination with TKI. This review discusses the place of SCT in the current therapy of CML. © 2012 Springer-Verlag Wien.
Garnett C, Giles C, Ahmed O, et al., 2012, Tandem Autologous Stem Cell Transplantation in Chemorefractory Multiple Myeloma, 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Publisher: AMER SOC HEMATOLOGY, ISSN: 0006-4971
Garnett C, Giles C, Lasa M, et al., 2012, Third Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma, 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Publisher: AMER SOC HEMATOLOGY, ISSN: 0006-4971
Tharmalingam H, Naresh K, Bain BJ, et al., 2012, Hypoplastic presentation of acute lymphoblastic leukemia, AMERICAN JOURNAL OF HEMATOLOGY, Vol: 87, Pages: 702-702, ISSN: 0361-8609
- Author Web Link
- Cite
- Citations: 2
Chaidos A, Patterson S, Szydlo R, et al., 2012, Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation, BLOOD, Vol: 119, Pages: 5030-5036, ISSN: 0006-4971
- Author Web Link
- Cite
- Citations: 110
Innes A, May PC, Pavlu J, et al., 2012, Unexpected pancytopenia following treatment of acute lymphoblastic leukemia, AMERICAN JOURNAL OF HEMATOLOGY, Vol: 87, Pages: 412-412, ISSN: 0361-8609
Kishore B, Davis J, Rezvani K, et al., 2012, Cryopreserved allogeneic peripheral blood stem cells result in outcome equivalent to those of fresh infusions enabling rational scheduling of donations, 38th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT), Publisher: NATURE PUBLISHING GROUP, Pages: S253-S254, ISSN: 0268-3369
- Author Web Link
- Cite
- Citations: 1
Auner HW, Pavlu J, Szydlo R, et al., 2012, Autologous haematopoietic stem cell transplantation in multiple myeloma patients from ethnic minority groups in an equal access healthcare system, BRITISH JOURNAL OF HAEMATOLOGY, Vol: 157, Pages: 125-127, ISSN: 0007-1048
- Author Web Link
- Cite
- Citations: 9
Pavlu J, Rezvani K, Kishore B, et al., 2012, Optimising patient selection for allogeneic stem cell transplantation: prediction of non-relapse mortality and survival, 38th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT), Publisher: NATURE PUBLISHING GROUP, Pages: S27-S28, ISSN: 0268-3369
Chakrabartty J, Pavlu J, Neave EL, et al., 2012, Safety and efficacy of two regimens of high-dose liposomal amphotericin B for prophylaxis of invasive fungal infection in allogeneic haematopoietic stem cell transplantation: a comparative retrospective single-centre study, 38th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT), Publisher: NATURE PUBLISHING GROUP, Pages: S131-S131, ISSN: 0268-3369
Beckerson J, Sampson B, Kanfer E, et al., 2012, Plasma zinc, copper and selenium in subjects planned for haematopoietic stem cell transplant and their change during treatment, 38th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT), Publisher: NATURE PUBLISHING GROUP, Pages: S192-S192, ISSN: 0268-3369
Rezvani K, Kanfer EJ, Marin D, et al., 2012, EBMT Risk Score Predicts Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Who Have Failed a Previous Transplantation Procedure, BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, Vol: 18, Pages: 235-240, ISSN: 1083-8791
- Author Web Link
- Cite
- Citations: 22
Al-Shieban S, Liu C, Fishlock K, et al., 2012, Bone marrow trephine biopsy findings in acute promyelocytic leukemia., Am J Hematol, Vol: 87, Pages: 109-110
Kishore B, Davis J, Rezvani K, et al., 2011, Cryopreserved Allogeneic Peripheral Blood Stem Cells Result in Outcome Equivalent to Those of Fresh Infusions Enabling Rational Scheduling of Donations, 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, Publisher: AMER SOC HEMATOLOGY, Pages: 1730-1731, ISSN: 0006-4971
Innes AJ, Lurkins J, Szydlo RM, et al., 2011, The Majority of Patients Receiving Donor Lymphocyte Infusions for Relapsed Chronic Myeloid Leukemia Remain PCR Positive Despite Maintaining Long-Term Remission, 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, Publisher: AMER SOC HEMATOLOGY, Pages: 1752-1752, ISSN: 0006-4971
- Author Web Link
- Cite
- Citations: 2
Pavlu J, Rezvani K, Kishore B, et al., 2011, Elevated Preconditioning Serum Levels of C-Reactive Protein Are Associated with Increased Nonrelapse Mortality and Inferior Survival After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation, 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, Publisher: AMER SOC HEMATOLOGY, Pages: 849-849, ISSN: 0006-4971
Pavlu J, Auner HW, Ellis S, et al., 2011, LACE-conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: treatment outcome and risk factor analysis from a single centre, HEMATOLOGICAL ONCOLOGY, Vol: 29, Pages: 75-80, ISSN: 0278-0232
- Author Web Link
- Cite
- Citations: 8
Pavlu J, Emmerson J, Marks AJ, et al., 2011, Idiopathic cytopenia of undetermined significance and the minimal criteria for a diagnosis of myelodysplastic syndrome, LEUKEMIA & LYMPHOMA, Vol: 52, Pages: 515-516, ISSN: 1042-8194
- Author Web Link
- Cite
- Citations: 5
de Lavallade H, Garland P, Sekine T, et al., 2011, Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host., Haematologica, Vol: 96, Pages: 307-314
BACKGROUND: In 2009 the declaration by the World Health Organization of a global pandemic of influenza-H1N1 virus led to a vaccination campaign to ensure protection for immunocompromised patients. The goal of this study was to determine the efficacy of the 2009 H1N1 vaccine in patients with hematologic malignancies. DESIGN AND METHODS: We evaluated humoral and cellular immune responses to 2009 H1N1 vaccine in 97 adults with hematologic malignancies and compared these responses with those in 25 adult controls. Patients received two injections of vaccine 21 days apart and the controls received one dose. Antibody titers were measured using a hemagglutination-inhibition assay on days 0, 21 and 49 after injection of the first dose. Cellular immune responses to H1N1 were determined on days 0 and 49. RESULTS: By day 21 post-vaccination, protective antibody titers of 1:32 or more were seen in 100% of controls compared to 39% of patients with B-cell malignancies (P<0.001), 46% of allogeneic stem cell transplant recipients (P<0.001) and 85% of patients with chronic myeloid leukemia (P=0.086). After a second dose, seroprotection rates increased to 68%, (P=0.008), 73%, (P=0.031), and 95% (P=0.5) in patients with B-cell malignancies, after allogeneic stem cell transplantation and with chronic myeloid leukemia, respectively. On the other hand, T-cell responses to H1N1 vaccine were not significantly different between patients and controls. CONCLUSIONS: These data demonstrate the efficacy of H1N1 vaccine in most patients with hematologic malignancies and support the recommendation for the administration of two doses of vaccine in immunocompromised patients. These results may contribute towards the development of evidence-based guidelines for influenza vaccination in such patients in the future.
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.